Foundation for the National Institutes of Health - Organization of the Year
Company: Foundation for the National Institutes of Health, Bethesda, MD
Company Description: The Foundation for the National Institutes of Health creates and leads alliances and public-private partnerships that advance breakthrough biomedical discoveries and improve the quality of people’s lives.
Nomination Category: Company/Organization Awards Categories
Nomination Sub Category: Organization of the Year – Government or Non-Profit– More Than 10 Employees
Nomination Title: Foundation for the National Institutes of Health
Describe for the judges the activities and accomplishments of the nominated organization since the beginning of July last year (up to 525 words):
Chartered by Congress in 1990, the Foundation for the National Institutes of Health (FNIH) forges public-private partnerships to advance breakthrough biomedical discoveries that can improve the quality of people’s lives, drawing together the world’s foremost researchers and resources in support of the mission of the National Institutes of Health (NIH). The FNIH is responsible for fundraising to support the 27 NIH institutes and centers. It facilitates the exchange of ideas among the private-sector and the public sector in a pre-competitive or non-competitive environment that would not be possible otherwise.
By early 2017, the FNIH reached the milestone of raising $1 billion from the private sector to advance biomedical research. Of every dollar raised by the FNIH, 94 percent directly supports programs. With this sound financial management, the FNIH has earned an “Exceeds Industry Standards” rating for 14 consecutive years from Charity Navigator. In 2016, it attained the highest ranking of 100 percent from this watchdog organization.
The funds raised by the FNIH have supported more than 600 programs in over 30 countries. These programs focus on a variety of topics from research to science training to patient care activities at the NIH and beyond. Recent accomplishments include:
-Raised $14 million from the private sector to fight Alzheimer’s disease through the launch of the third phase of the Alzheimer’s Disease Neuroimaging Initiative.
-Advanced two novel technologies for preventing the spread of mosquito-borne diseases (Dengue virus and malaria) to field testing through a longstanding partnership with the Bill & Melinda Gates Foundation.
-Brought together international experts to explore the complex regulatory and ethical issues surrounding mosquito modification technology and developed consensus to guide future research and regulations.
-Launched five collaborative projects through the FNIH Biomarkers Consortium with members from the NIH, FDA, pharmaceutical and biotechnology companies that will generate tools to advance therapy development in cancer, rheumatoid arthritis, frailty and heart disease.
-Released the “Framework for Defining Evidentiary Criteria for Biomarker Qualification,” which included input from 200 scientific leaders, as a tool to assess the level of evidence needed to support formal regulatory qualification of biological markers at the FDA.
-Met a critical milestone that could improve clinical trials and accelerate treatment approvals for hospital-acquired bacterial infections. Upon request from the FDA, the FNIH submitted recommendations to the FDA to guide drug development for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. The FDA will consider the recommendations as it develops clinical trial guidance for these serious infections that lead to increased deaths while patients are in the hospital.
-Continued building a critical pipeline of clinician scientists by supporting more than five training programs and fellowships at the NIH. This included the launch of an initiative to help developing nations build and expand their knowledge base and infrastructure in genetics and genomics through in-person training at the NIH.
-Upon request, FNIH leadership held several meetings on Capitol Hill to discuss the FNIH as a model example of a foundation that supports a government agency.
As a trusted resource for the scientific community, the FNIH will continue to lead efforts to shape the course of biomedical science and human health for decades to come.
Provide a brief biography of the person or persons who lead the nominated company (up to 125 words):
Dr. Maria Freire is the President and Executive Director of the Foundation for the National Institutes of Health (FNIH), a member of the U.S. National Academy of Medicine and Council on Foreign Relations. Dr. Freire is a sought-after expert in global health, technology commercialization and intellectual property management, focusing on the discovery, development and access to medical interventions for public good. Prior to the FNIH, Dr. Freire was the President of the Albert and Mary Lasker Foundation, where she established initiatives that expanded the brand and reach of the foundation. She previously served as President and Chief Executive Officer of the Global Alliance for TB Drug Development, a Product Development Partnership for drugs to fight tuberculosis, and directed the NIH Office of Technology Transfer.
Choose one (even if both apply): The CEO (or other principal manager) of this company is a woman, and at least 40% of the management team is comprised of women.